Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study.
absolute risk
competing risks
cumulative incidence function
flexible parametric survival model
inverse probability weighting
nested case-control studies
weighted likelihood
Journal
American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653
Informations de publication
Date de publication:
01 06 2019
01 06 2019
Historique:
received:
23
10
2017
revised:
28
01
2019
accepted:
29
01
2019
pubmed:
13
4
2019
medline:
11
2
2020
entrez:
13
4
2019
Statut:
ppublish
Résumé
In this paper, we describe the Prognostic Factors for Mortality in Prostate Cancer (ProMort) study and use it to demonstrate how the weighted likelihood method can be used in nested case-control studies to estimate both relative and absolute risks in the competing-risks setting. ProMort is a case-control study nested within the National Prostate Cancer Register (NPCR) of Sweden, comprising 1,710 men diagnosed with low- or intermediate-risk prostate cancer between 1998 and 2011 who died from prostate cancer (cases) and 1,710 matched controls. Cause-specific hazard ratios and cumulative incidence functions (CIFs) for prostate cancer death were estimated in ProMort using weighted flexible parametric models and compared with the corresponding estimates from the NPCR cohort. We further drew 1,500 random nested case-control subsamples of the NPCR cohort and quantified the bias in the hazard ratio and CIF estimates. Finally, we compared the ProMort estimates with those obtained by augmenting competing-risks cases and by augmenting both competing-risks cases and controls. The hazard ratios for prostate cancer death estimated in ProMort were comparable to those in the NPCR. The hazard ratios for dying from other causes were biased, which introduced bias in the CIFs estimated in the competing-risks setting. When augmenting both competing-risks cases and controls, the bias was reduced.
Identifiants
pubmed: 30976789
pii: 5320054
doi: 10.1093/aje/kwz026
pmc: PMC8210820
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1165-1173Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Int J Epidemiol. 2013 Aug;42(4):956-67
pubmed: 22561842
Lifetime Data Anal. 2015 Oct;21(4):517-41
pubmed: 25608704
Commun Stat Appl Methods. 2013 Nov;20(6):455-466
pubmed: 28503512
BMC Med Res Methodol. 2013 Feb 06;13:13
pubmed: 23384310
BMC Med Res Methodol. 2018 Dec 5;18(1):161
pubmed: 30518332
Nat Methods. 2012 Feb 28;9(3):245-53
pubmed: 22373911
Stat Med. 2014 Oct 30;33(24):4215-26
pubmed: 24919979
Biometrics. 1997 Jun;53(2):767-74
pubmed: 9192463
Biostatistics. 2012 Jan;13(1):89-100
pubmed: 21856652
Scand J Urol Nephrol. 2011 Sep;45(4):226-32
pubmed: 21463227
Int J Epidemiol. 2012 Jun;41(3):861-70
pubmed: 22253319
Stat Med. 2008 Dec 10;27(28):5991-6008
pubmed: 18792086
J Urol. 2007 Sep;178(3 Pt 2):S14-9
pubmed: 17644125
Eur Urol. 2013 Jan;63(1):88-96
pubmed: 22902040
BMJ. 2014 Jan 08;348:f7524
pubmed: 24401467
Stat Med. 2017 Feb 10;36(3):455-465
pubmed: 27734520
Eur J Epidemiol. 2015 Mar;30(3):197-207
pubmed: 25446306
Stat Med. 2013 Dec 30;32(30):5328-39
pubmed: 24132909
Am J Epidemiol. 2009 Jul 15;170(2):244-56
pubmed: 19494242
Epidemiology. 2014 Mar;25(2):315-7
pubmed: 24487222
Scand J Urol Nephrol. 2007;41(6):456-77
pubmed: 17934985
Scand J Urol Nephrol. 2008;42(4):352-7
pubmed: 18609293
Acta Oncol. 2015 Feb;54(2):158-63
pubmed: 25034349
Lifetime Data Anal. 2012 Jul;18(3):261-83
pubmed: 22382602
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Epidemiology. 2014 Jan;25(1):122-5
pubmed: 24240653